NB-PP_1170x120

Chuck Grassley

NACDS welcomes House drug disposal bill

NACDS welcomes House drug disposal bill

ARLINGTON, Va. – On the day before National Prescription Drug Take Back Day, the National Association of Chain Drug Stores today thanked the lead U.S. House of Representatives sponsors of H.R. 5628, the Access to Increased Drug Disposal Act of 2018, for their introduction of bipartisan legislation that is consistent with the spirit of NACDS’

Senate confirms Alex Azar as HHS secretary

Senate confirms Alex Azar as HHS secretary

WASHINGTON — Former Eli Lilly and Co. executive Alex Azar has been confirmed by the Senate as the new secretary of the U.S. Department of Health & Human Services (HHS). Nominated for the HHS secretary post in November by President Donald Trump, Azar was approved by the Senate on Wednesday in a 55-43 vote, mainly

Lawmakers push for action on drug costs

Lawmakers push for action on drug costs

WASHINGTON — Sens. John McCain (R., Ariz.) and Tammy Baldwin (D., Wis.) and Rep. Jan Schakowsky (D., Ill.) this week reintroduced the Fair Accountability and Innovative Research (FAIR) Drug Pricing Act, aimed at improving cost transparency for pharmaceutical price hikes. The FAIR Drug Pricing Act would require drug manufacturers to notify the Department of Health

Pharmacist provider status bill back in play

Pharmacist provider status bill back in play

WASHINGTON – Pharmacist provider status legislation is back before Congress, with the bipartisan co-sponsorship of more than a quarter of the Senate. Sens. Chuck Grassley (R., Iowa), Bob Casey (D., Penn.) and Sherrod Brown (D., Ohio) on Thursday reintroduced the Pharmacy and Medically Underserved Areas Enhancement Act (S. 109) with its 27 original co-sponsors. A

Mylan set to launch generic EpiPen

Mylan set to launch generic EpiPen

PITTSBURGH — In what chief executive officer Heather Bresch called “an extraordinary commercial response,” Mylan N.V. plans to release a generic version of its EpiPen epinephrine auto-injector for anaphylaxis, answering public demands to lower the cost of the potentially life-saving product. Mylan said Monday that its U.S. subsidiary expects to roll out the generic EpiPen

Senators question pricing of Mylan’s EpiPen

Senators question pricing of Mylan’s EpiPen

NEW YORK — Senate leaders have voiced concerns about a price surge for Mylan Inc.’s EpiPen, an epinephrine auto-injector for treating anaphylaxis, or potentially life-threatening allergic reactions. Sen. Chuck Grassley (R, Iowa), chairman of the Senate Judiciary Committee, and Sens. Susan Collins (R., Maine) and Claire McCaskill (D., Mo.), chairman and ranking member of the